SCHEMBL13204253

SCHEMBL13204253

CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](C(=O)Nc2cccc(C3CCOCC3)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.48
GAA P10253 2/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
USP2 O75604 1/20 0.46
HPGD P15428 1/20 0.46
ACKR3 P25106 2/20 0.43
GLA P06280 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RAB9A P51151 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
TYK2 P29597 1/20 0.40
BRAF P15056 1/20 0.40
AKT1 P31749 1/20 0.39
MAP4K4 O95819 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10114732 1.00 NPY5R (0.48) NPY5RGAALMNAHTTSMN1; SMN2
SCHEMBL10114673 0.87 NPY5R (0.51) NPY5RLMNASMN1; SMN2USP2GLA
SCHEMBL13204256 0.87 NPY5R (0.51) NPY5RLMNASMN1; SMN2USP2GLA
SCHEMBL10114285 0.84 TP53BP1 (0.50) NPY5RGAALMNAHTTSMN1; SMN2
SCHEMBL10113333 0.84 TP53BP1 (0.50) NPY5RGAALMNAHTTSMN1; SMN2
SCHEMBL13203717 0.82 NPY5R (0.53) NPY5RGAALMNAHTTSMN1; SMN2
SCHEMBL10114576 0.82 ALDH1A1 (0.56) NPY5RGAALMNAHTTSMN1; SMN2
SCHEMBL13203720 0.82 NPY5R (0.53) NPY5RGAALMNAHTTSMN1; SMN2
SCHEMBL10113273 0.82 NPY5R (0.53) NPY5RGAALMNAHTTSMN1; SMN2
SCHEMBL14424628 0.82 ALDH1A1 (0.56) NPY5RGAALMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R NPY5R 1/4885GAA 3448/4885LMNA 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.